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ABSTRACT 
Background 
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections 
(PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) are proposed 
diagnoses combining a clinical picture of acute onset obsessive compulsive disorder, tics or 
eating disorders with a suggested inflammatory pathogenesis. However, it remains uncertain 
if patients with PANS or PANDAS differ from other psychiatric patients with regard to 
symptoms, disorder course or symptom load at onset. Furthermore, there is currently a 
diagnostic test in clinical use, which aims to diagnose PANS and PANDAS, but its clinical 
validity is yet unclear. The proposed inflammatory pathogenesis of the disorders motivates 
immunomodulatory treatments, but the evidence for using such treatments is lacking.  
Aims 
 The aims of this thesis were to; describe a Swedish cohort of patients with PANS and 
PANDAS; evaluate the utility of the current diagnostic criteria for PANS and PANDAS; 
evaluate the diagnostic accuracy of the Cunningham Panel, a set of biomarkers aiming to 
diagnose PANS and PANDAS; establish if there are currently any evidence based treatments 
for PANS or PANDAS; and to describe the treatments given to a Swedish sample of patients 
with PANS and PANDAS, and the treatment effects. 
Methods 
This thesis comprises four studies with different study designs. Studies I, II and III were 
based on the same data collection. Study I is a case control study comparing Confirmed 
PANS (n=28), to Suspected PANS (n=29) and Never PANS (n=32) regarding symptoms, 
disorder onset and disorder course. Study II is a diagnostic accuracy study comparing 
Cunningham Panel results of Confirmed PANS (n=24), to Suspected PANS (n=29) and to a 
healthy comparison sample (n=21). Study III is a cross-sectional study of which treatments 
had been given to patients with Confirmed PANS (n=24) and Suspected PANS (n=29), 
treatment effects and patient satisfaction. Study IV is a systematic review of studies (n=12) 
and case reports (n=65) of treatment for PANS and PANDAS.  
Results 
In Study I we show that confirmed PANS (defined as acute onset) was associated to an 
episodic course and high symptom load at onset. According to the results of Study II the 
Cunningham Panel could not differentiate between Confirmed and Suspected PANS. In 
addition, healthy controls had elevated panel results on the Cunningham Panel. The results of 
Study III indicate that patients with PANS are possibly under-treated with standard 
psychiatric treatments. However, antibiotics and intravenous immunoglobulins were 
perceived as helpful by the participants. Treatment outcome predicted patient satisfaction. 
The literature reviewed in Study IV revealed that antibiotics, immunomodulatory 
  
medications and standard psychiatric treatment have been tried in PANS and PANDAS. The 
evidence for all studied treatments is inconclusive. 
Conclusion 
Episodic course, acute onset and high symptom load at onset are better specifiers of PANS 
than presence of specific symptoms. The Cunningham Panel is not a reliable diagnostic 
measure for PANS. When treating patients with PANS it is important to have knowledge of 
both psychiatric and immunomodulatory treatments. The lack of evidence based or effective 
treatments may lead to a low patient satisfaction. The field of PANS and PANDAS is in need 
of more and better research on the outcome of treatments. Key methodological issues include 
diagnostic challenges and lack of relevant outcome measures. 
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1 INTRODUCTION 
In psychiatry, the causes of disorders are largely unknown. Once the direct cause of a specific 
disorder becomes known, the disorder tends to migrate into other fields, such as neurology or 
infectious diseases. This means that within the psychiatric paradigm, looking for and treating 
the cause of a symptom is unusual. But as we gain more knowledge about the brain, genetics 
and the immune system, it may be hoped that pathophysiological mechanisms causing 
specific symptoms will be identified. 
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections 
(PANDAS)1 and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)2 are two 
proposed diagnoses combining a clinical picture involving certain severe psychiatric 
symptoms with a suggested inflammatory pathogenesis. The suggested inflammatory 
pathogenesis motivates treatment with medications unusual within the psychiatric field, like 
antibiotics and anti-inflammatory treatments.1, 2  
The idea of a severe neuropsychiatric disorder being curable by using something as simple as 
antibiotics or that a nonsteroidal anti-inflammatory drug can ameliorate psychiatric 
symptoms, poses both a promise and a challenge for clinicians and for families with an 
affected child. How can we tell if the child is best helped with behaviour therapy and 
psychotropic medication, or if anti-inflammatory agents should be prescribed? What if it is 
both? And if there is an inflammatory cause, does this mean that the diagnosis should be 
made using blood tests?  
This thesis is about children and adults presenting with very severe psychiatric symptoms, 
who report that immunological treatment alleviates their symptoms. Despite thirty years of 
clinical experience and research, the connections between the proposed cause, the symptoms 
and the treatments offered to these patients, remain uncertain. 
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2 BACKGROUND 
Obsessive compulsive disorder (OCD) is a psychiatric disorder defined by the presence of 
unwanted and intrusive thoughts (obsessions) and repetitive behaviours or mental acts 
(compulsions).3 Causes of OCD are unknown, but treatment with psychotropic medications 
and cognitive behavioural therapy (CBT) is often, but not always, successful. OCD can be a 
very debilitating disorder causing isolation and severe distress and it is associated with an 
elevated risk of suicide4 and metabolic complications5, as well as academic 
underachievement6 and labour market marginalization.7 Furthermore, OCD is often comorbid 
with tics, and autoimmune disorders are more common in individuals with OCD or tic 
disorder.8 OCD has also recently been associated with streptococcal infections on a 
population level.9 PANDAS and PANS are defined as presentations of OCD, tics or severe 
eating disorders, where an autoimmune pathogenesis is assumed. These entities are however 
not based on epidemiological data, but on clinical observations. 
2.1 DEFINITIONS OF PANS AND PANDAS 
2.1.1 PANDAS 
PANDAS was first defined by Susan Swedo and her colleagues in 1998.1 They described in 
detail 50 cases of this new clinical entity and established working criteria of PANDAS. 
Criteria of PANDAS are: (1) Presence of obsessive-compulsive disorder (OCD) or a tic 
disorder, (2) Pre-pubertal symptom onset, (3) Acute symptom onset and episodic (relapsing-
remitting) course, (4) Temporal association between Group A streptococcal infection and 
symptom onset/exacerbations, (5) Associated with neurological abnormalities, (particularly 
motor hyperactivity and choreiform movements).1 All five criteria must be met. PANDAS 
was not defined as a disorder of its own, but rather as a proposed clinical concept suggesting 
a pathophysiology for a subgroup of OCD or tics patients fulfilling these criteria.  
In Swedo’s first study a total of 144 periods of symptom exacerbations with a known 
relationship with streptococcal infections were reported. Of these 144 periods of 
exacerbation, 23% were not preceded by streptococcal infection within the preceding month.1 
The study also described some key clinical features of PANDAS that are not part of the 
diagnostic criteria, such as separation anxiety, deterioration in handwriting and choreiform 
movements. The first 50 patients also reported high rates of psychiatric comorbidity, 
including 66% reporting emotional lability and 54% reporting personality change.1 The 
clinical criteria for PANDAS proposed in 1998 are still the ones in clinical use. 
2.1.2 From PANDAS to PANS 
In 2012 Swedo, Leckman and Rose presented new and wider diagnostic criteria for Pediatric 
Acute Neuropsychiatric Syndrome (PANS).2 During the years of clinical work and research, 
several researchers reported excluding cases from studies due to not having streptococcal 
infections preceding the symptoms. PANS is described in this first, defining paper as an 
umbrella term for conditions including an abrupt onset of obsessive compulsive disorder or 
restricted eating. Proposed diagnostic criteria for PANS are (i) sudden onset (< 72h) of OCD 
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or restricted eating; (ii) at least two of the following: anxiety, mood or behaviour 
disturbances, irritability or aggression, developmental regression, deterioration in school 
performance, sensory or motor abnormalities, and somatic symptoms; and (iii) symptoms 
may not be better explained by any known medical or neurological disorder.2 The clinical 
characterization of the syndrome still includes somatic and neuropsychiatric symptoms, such 
as severe anxiety and irritability, and deterioration in school performance or handwriting. The 
authors stated that the goal of the new criteria was to improve comparability of research 
samples.2 
In 2015, the first systematic case series using the new criteria was published.10 Using the 
proposed criteria, the authors identified 43 youths with PANS. This paper presented a clinical 
picture similar to the samples with PANDAS such as severe and mixed psychiatric 
symptoms, including irritability, anxiety, self-harm or harm to others, frequent urination and 
deterioration of hand writing.10 
Treatment options for PANS are not as well defined as they are for PANDAS, and there is 
very little systematic literature on the treatment of PANS. The lack of a united 
pathophysiological theory for PANS limits the possibilities of proposing viable treatment 
options. However, a consensus conference held in 201311 suggested that a very thorough 
workup including psychiatric, psychological, immunological and rheumatological signs and 
symptoms should be assessed and recorded when suspecting PANS. The combination of 
possible immunological markers and the severity of the symptoms that the patients present 
may motivate immunomodulatory treatment of these patients. 
Another suggestion of a new diagnostic entity for patients presenting with acute onset 
neuropsychiatric symptoms but no evidence of streptococcal infection is Childhood acute 
Neuropsychiatric Symptoms (CANS).12 The proposed diagnostic criteria for CANS are very 
similar to PANS criteria, requiring acute onset of OCD in combination with other psychiatric 
and somatic symptoms. CANS is a more conservative entity with regards to proposed 
pathophysiology than PANS and PANDAS, and the authors make no claims towards any 
immunological pathogenesis and discourage immunological treatment.12  
2.1.3 The proposed pathophysiology of PANDAS 
The proposed pathophysiology of PANDAS is similar to that in Sydenham’s chorea or 
rheumatic fever, where a streptococcal infection triggers an antibody mediated immune 
response to autoantigen in the basal ganglia, thereby causing disturbances in movement and 
behaviour.13 
Although PANDAS is not defined as an autoimmune disorder by the diagnostic criteria, there 
is some support for an autoimmune etiology.14-16 For instance, PANDAS has a similar 
clinical picture, with sudden onset and movement disorder, as Sydenham’s Chorea, which is 
an autoimmune disorder known to be triggered by a streptococcal infection.1, 16 Further, there 
are case studies and clinical reports of PANDAS-cases being improved when treated with 
immunomodulatory medication.17, 18 Lastly, PANDAS-cases are proposed to have elevated 
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levels of antibodies to surface structures of nerve-cells, specifically the receptors Dopamine 
D1 and D2, to β-tubulin and lyso-ganglioside, supporting an auto-immune etiology.19  
In the original paper from 1998, the following pathogenic model of PANDAS was proposed: 
“Pathogen + Susceptible host → Immune response → Sydenham Chorea or PANDAS 
(neuropsychiatric symptoms)”1. The paper however did not present autoimmune features of 
PANDAS, but instead defined the disorder with regard to symptoms (OCD and or tics), 
course (pre-pubertal onset and abrupt onset, abrupt exacerbations) and signs of streptococcal 
infection. In the first description of 4 cases with what was then referred to as pediatric 
infection triggered autoimmune neuropsychiatric disorders (PITANDs), Dr. Swedo and her 
colleagues described the patients’ immunological profiles, and one was positive for anti-
nuclear antibodies.20 Furthermore, these four patients were treated with plasmapheresis, 
Prednisone and intravenous immunoglobulin (IVIG). All four patients improved after 
treatments, consistent with an immunological or autoimmune pathogenesis. Neither PANS 
nor PANDAS are thus defined by autoimmune features in the diagnostic criteria. However, 
both entities have been used to describe patients where the suspected pathophysiology is 
autoimmune.  
2.2 DIAGNOSIS OF PANS AND PANDAS 
Diagnosis of PANS and PANDAS is made by careful clinical assessment. According to a 
paper written during a PANS Consensus Conference in 2013, clinical evaluation of suspected 
PANS should include: family history, medical history and physical examination, psychiatric 
evaluation, evaluation of present infections, assessment of symptoms and history indicating 
immune dysregulation, neurological assessment, assessment of somatic symptoms and 
genetic evaluation.11 This extensive evaluation is necessary to rule out other causes of 
symptoms and to be able to differentiate PANS from psychiatric disorders (including non-
PANS OCD, Tourette syndrome and bipolar disorder) and somatic disorders including 
autoimmune encephalitis, Sydenham chorea and systemic autoimmune disease.11 In the paper 
first describing PANS, it is underlined that PANS-symptoms should be new, rather than 
chronic, and that for instance visuospatial deficits commonly seen in children with tic 
disorders or OCD are not necessarily signs of PANS, unless they manifest suddenly and a 
clear deterioration can be seen.2  
2.2.1 Temporal association to streptococcal infections 
A PANDAS diagnosis requires a temporal association with a streptococcal infection 
occurring before disorder onset or a severe exacerbation of symptoms. However, this 
connection has been difficult to prove. One study followed 40 PANDAS cases and a 
comparison sample of 40 non-PANDAS OCD cases for two years, and in this sample, 
streptococcal infections were indeed more common in the PANDAS group, but infections 
could only be temporally connected to 5 out of 64 exacerbations recorded.21 This result has 
been replicated in a later study comparing 31 PANDAS cases to 53 non PANDAS OCD or 
tic cases.22 Moreover, serum levels of antibodies and throat cultures may be positive for a 
long time after infection, and thus do not always indicate a current infection.23 
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2.2.2 The Cunningham Panel 
A panel of antibodies to receptors Dopamine D1 and D2, to β-tubulin and lyso-ganglioside, in 
combination with calcium/calmodulin-dependent protein kinase II activity (CaMKII), the 
Cunningham Panel, is proposed to be specific for PANS, thus potentially aiding physicians in 
the complex task of diagnosing and treating PANS.24 However, the Cunningham Panel has 
not been systematically evaluated as a diagnostic tool for PANS or PANDAS. One study 
showed elevated levels of antibodies to dopamine receptor D1 and lyso-ganglioside as well as 
increased CaMKII in 261 youth with OCD or tics and confirmed streptococcal infection, but 
not specifically PANS or PANDAS diagnosis.19 This suggests that these biomarkers may not 
be specific to PANS or PANDAS. Another study has compared Cunningham Panel results of 
children with PANDAS before, during and after symptom exacerbation, and found no 
correlation between symptom severity and antibody titres.25 However, the sample size was 
small (n=12) and CaMKII was not included in the analysis. 
2.2.3 Differential diagnostic challenges 
There are no valid instruments for accurately measuring the acute onset, the episodic course 
or deterioration rather than deficits that are the hallmark signs of PANS and PANDAS. 
Furthermore, data from a specialist clinic dedicated to the diagnosis and treatment of PANS 
have suggested that the acute onset criterion does not identify patients with positive immune 
markers, a relapsing/remitting course or specific symptom presentations.26 Similar differential 
diagnostic challenges have arisen in PANDAS. A comparison of 41 cases with PANDAS (i.e. 
streptococcal infection preceding illness) with 68 non-PANDAS OCD or tic disorder cases 
showed differences between groups regarding strep related outcomes (e.g. positive throat 
cultures and frequent previous streptococcal infections), but not other key symptoms of 
PANDAS like presence of dramatic flares, separation anxiety, enuresis and deterioration in 
school performance or hand writing.27 This combination of lack of valid instruments and a 
documented difficulty in separating cases from non-cases using the diagnostic criteria poses a 
challenge to the whole field of PANS and PANDAS.  
2.3 TREATMENT OF PANS AND PANDAS 
The proposed pathophysiology of PANDAS opens up a window to treatment options usually 
not considered in psychiatry. Treatments evaluated in literature include (i) different kinds of 
antibiotics for treating streptococcal infections,28-31 (ii) plasma exchange for removing 
antibodies from the blood,18, 32 (iii) intravenous immunoglobulin (IVIG) which is used 
because of the proposed mediation of symptoms by autoantibodies,32-34 and (iv) Cognitive 
behavioural therapy (CBT) for the obsessive compulsive symptoms.35, 36 There is less 
literature on the treatment of PANS, but antibiotics30, CBT35, corticosteroids37 and non-
steroidal anti-inflammatory drugs (NSAIDs)38 have been tried. Results are mostly 
inconclusive, possibly due to the small sample sizes and uncontrolled study designs.  
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2.4 CONCLUSION AND RATIONALE OF THIS THESIS 
PANS and PANDAS are diagnostic entities that seem to be clinically valuable, although their 
validity is still unclear. PANS and PANDAS are currently treated under an immunological 
paradigm in many places in the world, but the evidence for immunological treatments is 
unclear. Consequently, we wished to collect a sample of patients with PANS or PANDAS, to 
study their symptoms onset and course, and to compare them with psychiatric patients 
without PANS or PANDAS in order to test if the diagnostic criteria are indeed specific to 
these disorders. We also wished to study which treatments they had been given, and how the 
treatment effects were perceived by the patients.  
A blood test panel on the market (the Cunningham Panel) claims to be able to diagnose 
PANS and PANDAS, but the diagnostic accuracy of the test has not been tested in a 
systematic way. An invalid diagnostic test may lead to incorrect diagnoses and thereby to 
incorrect treatment. On the other hand, a valid diagnostic test which has not been 
systematically evaluated may be underused in clinical practice due to lack of formal 
evidence. For these reasons, we wished to study the diagnostic accuracy of the Cunningham 
Panel. 
In addition to studying treatment given to Swedish patients, we wanted to systematically 
review all of the available literature on PANS and PANDAS treatment in order to establish if 
any of the treatments currently in clinical use are supported by evidence.    
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3 AIMS 
The aims of this thesis are to 
a. Describe a Swedish cohort of patients with PANS and PANDAS. 
b. Evaluate the utility of the current diagnostic criteria for PANS and PANDAS. 
c. Evaluate the diagnostic accuracy of the Cunningham Panel, a set of biomarkers 
aiming to diagnose PANS and PANDAS. 
d. Establish if there are currently any evidence-based treatments for PANS or PANDAS. 
e. Describe the treatments given to a Swedish sample of patients with PANS and 
PANDAS, and the treatment effects. 
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4 METHODS 
4.1 PARTICIPANTS AND RECRUITMENT 
4.1.1 Studies I, II and III 
Studies I, II and III are all based on the same data collection in which we recruited and 
assessed 53 patients who had taken the Cunningham panel (Cunningham Panel sample, 
presented in studies I, II and III); 36 psychiatric patients with no suspicion of PANS or 
PANDAS who served as a psychiatric comparison sample in study I (Örebro sample); and 21 
healthy persons who served as a healthy comparison sample in study II (Healthy sample). 
The three empirical papers included in this thesis are based on the assumption that the 
participants in the Cunningham Panel sample had been suspected of having PANS or 
PANDAS by their treating physician. Furthermore, we classified these participants into two 
groups: those who fulfilled the criteria for PANS, PANDAS or both disorders, and those who 
did not. We call these two groups “Interview Confirmed PANS” and “Suspected PANS” 
respectively. See Figure 1 for a flowchart of the samples used in this thesis.  
Figure 1. Flowchart of participant inclusion. The three empirical studies in this thesis are 
based on the same data collection.  
4.1.2 The study sample - participants with suspected PANS and PANDAS. 
The study sample of this thesis is comprised of the 53 patients who had previously taken a 
Cunningham Panel. All patients who had taken the panel in Sweden prior to June 2014 were 
invited to participate in the study (n=154), regardless of their results on the panel. The 
Cunningham Panel was only used as a means for inclusion, and not to support a diagnosis of 
PANS or PANDAS in the studies included in this thesis.  
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The reasons for using this method of recruitment of our study sample were three. Firstly, we 
wanted to identify a sample of patients with suspected PANS and PANDAS who had been 
identified by several different physicians, as opposed to from one clinic. Secondly, we 
wanted to recruit a sample of participants who were representative of the patients that were 
likely to be offered a Cunningham Panel on clinical indication, in order to adhere with 
Standards for Reporting Diagnostic accuracy studies (STARD guidelines).39 Thirdly, by 
inviting all patients who had been clinically assessed with the Cunningham Panel, we could 
identify our study sample within a limited amount of time. 
The only inclusion criterion for this sample was to have previously taken a Cunningham 
Panel. Exclusion criteria were being over the age of 40, and inability to complete the 
assessment in Swedish. In the original study plan, patients with intellectual disability were 
also excluded. However, several participants who had taken the Cunningham Panel had a 
diagnosis of intellectual disability, and to ensure representability in our sample we also 
wanted to include these participants. This change in inclusion criteria was approved by the 
ethical review board of Stockholm at Karolinska Institutet. 
4.1.3 The Örebro Sample - a psychiatric comparison sample 
In order to assess if clinical features reported to be specific for PANS were also common 
among psychiatric patients with no suspicion of PANS, we recruited a sex and gender 
matched sample of patients with any psychiatric disorder, not suspected to have PANS 
(n=36). The inclusion criteria for this sample were: a) to have a current psychiatric condition 
that required specialist care, b) to be age and gender matched to a participant in the study 
sample recruited through the Cunningham Panel and, c) to be able to complete the assessment 
in Swedish. These participants were mostly recruited through psychiatric services in Region 
Örebro Län, Sweden.  
4.1.4 The healthy comparison sample 
In study II, we assessed the diagnostic accuracy of the Cunningham Panel using a clinical 
sample of psychiatric patients likely to be tested with the panel in a clinical setting. To further 
assess the clinical value of the Cunningham Panel we also wished to test a healthy 
comparison sample. We recruited 21 healthy persons who were gender and age matched to 
the study sample recruited through the Cunningham Panel. The inclusion criteria for this 
group was to be gender and age matched to the study sample recruited through the 
Cunningham Panel. Exclusion criteria were a) to have or to have had a psychiatric diagnosis, 
b) to have been a patient of a psychiatric outpatient unit during the last year, c) to have or 
have been treated for an autoimmune disorder, or d) to have or have had a disorder that gives 
motor abnormalities. The exclusion criteria were assessed using a short questionnaire and 
validated by an interview with a medical doctor.  
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4.2 PROCEDURE OF STUDIES I, II AND III 
4.2.1 Data collection procedure 
The study sample recruited through the Cunningham Panel and the psychiatric comparison 
sample underwent a thorough psychiatric assessment including both validated and non-
validated structured measures of psychiatric and medical history, current symptoms, 
treatments received, motor abnormalities and cognitive function. The assessments were 
performed in in- and outpatient settings across Sweden, and in the participants’ homes. The 
participants were both children and adults, and varied greatly in functional level. All children 
and most adults were accompanied and assisted by a parent during the assessment.  
The data collection is cross-sectional, meaning that we assessed all participants at one time-
point during the course of their illness. This means that we did not collect data before and 
after any treatments or other interventions, and we do not have any longitudinal data in our 
dataset. However, due to the length of the interview and to the low functioning of many of the 
participants, some interviews were made during several sittings.  
All interviews were made by two researchers. All participants in the Cunningham Panel 
sample were interviewed by Susanne Bejerot, MD, PhD and professor of psychiatry at 
Örebro University, and myself, who is trained in clinical psychology. Participants in the 
Örebro sample were assessed by either professor Bejerot or Dr. Machi Cleanthous, MD, 
specialist in psychiatry, and myself or Jasmina Popaja, licenced psychologist. All interviews 
took place during the years 2015 or 2016. Dr. Machi Cleantous alone assessed the healthy 
comparison sample.  
In this thesis and in the papers herein, the data was collected using structured interviews, and 
is therefore described as self-rated retrospective data. Each interview was performed with 
regard to each participants’ ability and willingness to participate. When the participant was 
unable to answer questions, due to e.g. low age, shyness, fatigue, lack of spoken language, 
intellectual disability, or unwillingness to participate, the interview was made with the 
accompanying parent. We performed all interviews with respect for each participants’ 
integrity and right to autonomy. We chose not to exclude any participant due to non-
participation, thus we allowed for non-participation in all elements of the interviews, the 
motor- and cognitive assessments and the blood tests. We have also chosen to use the term 
“self-rated” to describe the data collected, although in some cases it is “parent-rated”. 
We started the interviews by explaining the rational for the study and collecting formal 
consent for participation. After this we often split up, with one person interviewing the 
participant, or doing the motor and cognitive testing, and the other interviewing the parent 
using one of the structured interviews that the clinical assessment was based on. By splitting 
up this way we allowed participants and parent to speak more freely about the medical history 
and current symptoms. We tried to observe as many symptoms as possible during the 
assessments, and the length of the interviews made it easier to observe some aspects of PANS 
and PANDAS symptomatology, i.e., tics, fatigue, attention difficulties and separation anxiety. 
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However, many of the symptoms reported were not present during the assessments and were 
only rated in retrospect.  
Blood samples were drawn at a clinic local to the participant. The healthy comparison sample 
was only assessed briefly in order to rule out persons who met exclusion criteria. 
4.2.2 Blinding and study integrity 
In order to protect the clinical diagnoses we made from being influenced by a previous 
Cunningham Panel result, we were blinded to Cunningham Panel results at the time of 
assessment. Wieslab and Moleculera labs were blinded to the identity of all participants, but 
knew their gender and age. 
4.3 MEASURES USED IN STUDIES I, II AND III 
4.3.1 Measures of PANS and PANDAS symptoms and how we made the 
diagnoses 
PANS and PANDAS are both clinical diagnoses, made on clinical signs of the psychiatric 
presentation of the patient and not by any biomarker or overt sign of inflammation. The 
criteria state that certain symptoms must be present, and that they follow a specific course and 
onset. At present, there are no validated measures with sound psychometric properties for 
diagnosing PANS or PANDAS. In our study, and in many others, evaluation of the course 
and the onset was made in retrospect, long after the initial presentation of the symptoms. 
However, most standard measures of psychiatric symptoms ask for the patients’ current 
psychiatric status, and are therefore not always appropriate for evaluation of a disorder with a 
relapsing or remitting course such as PANS or PANDAS. We used two major tools for 
assessing PANS and PANDAS symptoms, onset and course. Firstly, we used the PANS 
Scale-Revised (PANS Scale-R), which is an unpublished scale developed by professor James 
Leckman and coworkers who generously shared their scale with us for use in these studies. 
We also developed a structured interview of medical history, with focus on onset, course and 
PANS-related symptoms. This assessment comprised several parts, and covered general 
medical history, general psychiatric history, and PANS related symptoms, onset and course. 
4.3.1.1 PANS Scale-R 
The PANS Scale-R is an unpublished structured interview developed by Dr. Jim Leckman 
and colleagues (Leckman, personal communication). It comprises four parts: a) two open 
ended questions asking the informant to describe the initial PANS symptoms and to describe 
the onset and specify if it was acute or gradual; b) a checklist of five OCD symptom themes 
and eating disorder, each described using the variables “present now”, “present ever”, “date 
of onset” and “clinician verified”; c) a checklist of other related PANS symptoms each 
described using the variables “present now”, “present ever”, “date of onset” and “clinician 
verified”; d) an assessment of function, where the three most debilitating symptoms are 
noted, and the severity of OCD, restrictive eating, current PANS symptoms, and global 
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function are rated. The PANS Scale-R has been used in previous descriptions of PANS-
samples at Stanford University26 and at Göteborg University.40 
4.3.1.2 PANS/PANDAS Related Symptom Inventory (PPRSI) and The Signs of Severity 
Questionnaire (SOSQ) 
We developed the two questionnaires PANS/PANDAS Related Symptom Inventory (PPRSI) 
and Signs of Severity Questionnaire (SOSQ) for the data collection, and they are presented in  
the supplementary material of Study I. We wanted to assess all present and past PANS 
related symptoms. We also wanted to assess the onset and course of each symptom. 
Furthermore, we were interested to find out if the patients in our Swedish cohort had  
psychiatric symptoms before the onset of PANS, or if they were mostly healthy before the 
acute onset of PANS symptoms. We also wanted to assess if each symptom was experienced 
as being present at only at exacerbations or in episodes, rather than being chronic, gradual or 
otherwise non-episodic. See figure 2 for details on layout and items included in PPRSI.  
Figure 2. The instrument PPRSI which we developed for use in this study. 
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SOSQ follows the same structure. PANS onset, or onset of the symptoms suspected to be 
PANS, was defined in the beginning of the interview. In the Örebro sample, we used the date 
of onset of the most relevant current psychiatric disorder as experienced by the participant. 
The PPRSI comprises psychiatric symptoms related to PANS, i.e. noted in diagnostic criteria 
or otherwise prevalent in PANS cases in previous literature. The SOSQ comprises severe 
psychiatric symptoms not specifically related to PANS, such as suicidal ideation or actions, 
violence or psychotic symptoms.  
4.3.1.3 Measure of acute onset 
In addition to the open-ended questions of PANS Scale-R and the detailed assessment of the 
onset and course of all symptoms, we also included one item in the structured interview that 
specifically asked for the time from onset to maximum symptoms of that episode. 
Participants were asked to rate if it was: shorter than 24 hours, between 24 and 72 hours, 72 
hours to 14 days or more than 14 days. This was not an entirely self-rated item, during the 
interview the psychiatrist asked about details of the onset. The final score of this item was 
noted by the clinician and based on all information available during the assessment.  
4.3.1.4 Measure of disorder course 
Beside the PPRSI and the SOSQ we also included a general measure of disorder course. 
Participants were shown a picture depicting eight different courses, depicting both chronic 
and relapsing remitting variants of a disorder course, see figure 3. Participants were asked to 
choose the one picture that best described their disorder course. If there was no fitting 
alternative, they could choose “other” and then draw their own picture. 
 
Figure 3. The instrument used to describe disorder course. 
4.3.1.5 How we made the classification of PANS and PANDAS 
One of the central premises for Study I, II and III is that we made a classification of the 
participants, deciding if they fulfilled criteria for PANS or PANDAS using all available 
information gathered during the assessment. We used the PANDAS1 and PANS2 criteria  
shown in table 1. At the end of the assessment, both present assessors agreed on whether or 
not each participant fulfilled each criterion for any or both disorders.  
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4.3.2 Standard psychiatric measures  
4.3.2.1 The Mini International Neuropsychiatric Interview (M.I.N.I.and MINI-KID) 
The Mini International Neuropsychiatric Interview, version 6 (M.I.N.I.)41 is a structured 
interview for assessing multiple present and previous psychiatric diagnoses. In the current 
study, we used the M.I.N.I. version 6 for adults and the MINI-KID42 version 6 for children. 
The MINI-KID includes several items not included in the M.I.N.I. for adults. To ensure the 
assessments between adults and children were compatible, we decided to include the MINI-
KID modules of the following diagnoses in the interview of the adult participants: separation 
anxiety, specific phobias, Tourette syndrome/tics, attention deficit hyperactivity disorder 
(ADHD), conduct disorder, and oppositional defiant disorder. M.I.N.I. and MINI-KID have 
been translated into Swedish, but the translation/validation has not been published in an 
academic journal. On the official website for M.I.N.I., Swedish is listed as one of the 
languages to which the instrument has been officially translated. The M.I.N.I. interviews are 
widely used in clinical practice in Sweden.  
In studies I, II and III, we used M.I.N.I. to establish which psychiatric disorders the 
participant had at the time of the assessment. In studies I and III, we have also presented a 
composite score of number of psychiatric diagnoses present according to M.I.N.I., thereby 
using it as a measure of psychiatric severity or complexity. 
Table 1. Diagnostic criteria for PANS and PANDAS 
PANDAS1 PANS2 
All 5 criteria must be met. Criteria I, II and III must be met 
1) Presence of obsessive-compulsive disorder (OCD) 
or a tic disorder. 
2) Prepubertal symptom onset. 
3) Acute symptom onset and episodic (relapsing-
remitting) course. 
4) Temporal association between Group A 
streptococcal infection and symptom 
onset/exacerbations. 
5) Associated with neurological abnormalities, 
(particularly motoric hyperactivity and choreiform 
movements) 
 
 
 
 
 
 
I. Abrupt, dramatic onset of obsessive-compulsive 
disorder or severely restricted food intake 
II. Concurrent presence of additional neuropsychiatric 
symptoms, with similarly severe and acute onset, from 
at least two of the following seven categories: 
1. Anxiety  
2. Emotional lability and/or depression  
3. Irritability, aggression and/or severely 
oppositional behaviours  
4. Behavioural (developmental) regression  
5. Deterioration in school performance 
6. Sensory or motor abnormalities  
7. Somatic signs and symptoms, including sleep 
disturbances, enuresis, or urinary frequency  
III. Symptoms are not better explained by a known 
neurologic or medical disorder, such as Sydenham 
chorea, systemic lupus erythematosus, Tourette 
disorder or others. 
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4.3.2.2 The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) 
The Yale-Brown Obsessive Compulsive Scale (Y-BOCS)43 and the Children’s Yale-Brown 
Obsessive Compulsive Scale (CY-BOCS)44 are clinician rated instruments for assessing 
current severity of OCD. They both range from 0 to 40 points, with a higher score indicating 
higher severity of OCD. Y-BOCS and CY-BOCS have both been previously translated into 
Swedish and are widely used in clinical and research settings in Sweden. However, there is 
no publically available data on the psychometric properties of the Swedish versions of the 
scales. In studies I and III we present Y-BOCS and CY-BOCS scores as demographic data.   
4.3.2.3 Clinical global Impression -Improvement and -Severity (CGI-I and CGI-S) 
The Clinical Global Impression-Severity (CGI-S) and The Clinical Global Impression-
Improvement (CGI-I) are two single item, clinician rated measure of global severity or global 
improvement.45 These clinician rated measures are considered a gold standard measure of 
severity and improvement in psychiatry, and are used in many treatment trials and for many 
psychiatric disorders. The CGI-S ranges from 1 to 7 points, with a score of 7 indicating a high 
severity, a score of 4 corresponding to “moderately ill” and a score of 1 corresponding to “no 
illness”. The CGI-I ranges from 1= “very much improved” to 7= ”very much worse”, with 4 
being a neutral score of “no change”. 
In the data collection, that is the foundation of this thesis and of the papers herein, the CGI-S 
was rated by a clinician at the end of each interview, taking all available information into 
account. The CGI-I however, was used as a self-rated measure, where the participants were 
asked to rate change in symptoms since the day that they took the first Cunningham Panel 
test. 
4.3.3 Assessment of treatments given and patient rated treatment effects 
4.3.3.1 Specific treatments 
Each participant was asked if they had received any of a number of treatments commonly 
given for psychiatric symptoms, as well as immunological treatments sometimes 
recommended for PANS or PANDAS. Time, dose and duration was recorded for each 
treatment. If the participant had received a treatment, we recorded if it was given before or 
after onset of PANS and if the participant is currently on the treatment. Treatment effects 
were rated as “none”, “worse”, “little better” or “much better”. We also recorded if each 
treatment had been given for PANS or PANDAS.  
4.3.4 Assessment of patient satisfaction 
The Client satisfaction questionnaire (CSQ) was used to measure global patient satisfaction.46 
The CSQ comprises eight items and is a commonly used instrument to measure patients’ 
satisfaction within clinical care. The items are phrased as questions such as “How would you 
rate the quality of the service you received?” and each item is rated on an individual scale 
from 1 to 4 (e.g.: poor=1; fair=2; good=3; excellent=4). The items cover quality of service, if 
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the patient got the service they wanted, if the service met the patient’s needs, if the patient 
would recommend the service to others, if the patient is satisfied with the services and with 
the amount of services, if the service has helped, and if the patient would seek help in the 
same place again. CSQ ranges from 8 to 32 points and higher scores indicate higher 
satisfaction. CSQ has been translated into Swedish by the original author and copyright 
holder, but there is no published information about the translation, except a statement on the 
instrument webpage that there is a Swedish translation.47 The instrument is widely used is 
Sweden.  
4.3.5 Cognitive assessments 
The clinical assessment included four sections of the Wechsler intelligence scales for adults 
(WAIS-IV)48 or children (WISC-III)49; block design, letter number sequencing, digit symbol 
coding, and digit span. A full scale IQ of each participant was estimated using the mean of 
the four scaled scores available and multiplying them by 11.48, 49 
4.3.6 Biological measures  
4.3.6.1 The Cunningham Panel 
The Cunningham Panel was performed by Moleculera Labs. This study was not done in 
collaboration with Moleculera. We did collaborate with Moleculera’s European partner 
laboratory, Wieslab (Lund, Sweden) and we paid a slightly discounted market price for each 
analysis. All Cunningham Panel samples ordered within the study were administered by 
Wieslab. The Cunningham Panel comprises five analytes: antibodies to dopamine receptors 
D1 and D2, β-tubulin and lyso-ganglioside, and calcium/calmodulin-dependent protein kinase 
II activity (CaMKII). The antibodies are measured with enzyme-linked immunosorbent assay 
(ELISA) and the results are presented as antibody titres. The CaMKII is measured using a 
cell-based assay and results are presented as percentage activation.  
We used two Cunningham Panel results taken at two different time points in this study. The 
first time-point was the first recorded Cunningham Panel result available in Wieslab’s 
records. The second time-point and the testing of all our comparison individuals was ordered 
by us, following Wieslab’s instructions for sample collection. All samples were taken at a lab 
local to the patient. The serum was centrifuged, and then sent to Wieslab to be aliquoted and 
frozen. Wieslab sent the frozen samples to Moleculera who performed the panel per their 
standard operating procedure. Moleculera then sent a test report with results to Wieslab, who 
printed the report and sent it to us. 
At the time of our study, Wieslab’s instructions for sampling for the Cunningham Panel was 
to use serum collection tubes with a separator gel (Gold Top tubes) or without a separator gel 
(Red Top tubes) for collection of serum. In Sweden it is uncommon to use glass tubes, and 
therefore we assume that most samples from the first time point were taken using plastic 
tubes with or without a separator gel. All tests ordered by us within the study (i.e. all tests at 
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the second time point and all samples from the healthy control sample) were taken in plastic 
tubes using a separator gel (BD Vacutainer® SST™ II Advance tubes, Gold Top).  
Moleculera has later stated that they recommend glass tubes with no additives (glass Red Top 
tubes) for serum collection for the Cunningham Panel.50 
4.3.6.2 Other biological measures 
In order to get a marker of current inflammation or infection, we also measured C-reactive 
protein in plasma and erythrocyte sedimentation rate in blood. Both these analyses were 
conducted according to standard clinical procedure at the time of assessment. Height and 
weight were reported during interview and used to estimate body mass index. 
4.4 STUDY DESIGNS AND STATISTICAL METHODS IN STUDIES I, II AND III 
4.4.1 Study I - Clinical features of pediatric acute-onset neuropsychiatric 
syndrome: Findings from a case–control study 
The aims of this study were to determine if patients who meet full PANS criteria can be 
differentiated from patients with suspected PANS, or other psychiatric patients, regarding the 
presence of PANS related symptoms, amount of symptoms at onset, episodic course or 
sudden onset of symptoms. The study design is a case control study, and the participants were 
recruited because they had previously taken the Cunningham Panel or as psychiatric 
comparison participants. The participants were divided into three groups: Interview 
confirmed PANS, Suspected PANS and Never PANS (see figure 1 for details). We presented 
and compared the three groups by demographic data, including gender, age, rough markers of 
inflammation, and estimate of intellectual ability. 
Psychiatric symptoms were assessed using the PANS Scale-R. Episodic course and sudden 
onset were assessed using the instruments developed for use in this study. In order to test if 
some symptoms were more prevalent in any group, the frequency of each symptom was 
compared between the three groups using 3x2 χ2 tests. In order to test if participants with 
confirmed PANS reported the presence of more symptoms at onset, we compared the relative 
proportion of PANS related and severe symptoms present before onset, at onset and after 
onset using 3x3 χ2 tests. In order to test if participants with confirmed PANS experienced 
more symptoms with an episodic course, we compared the relative frequency of symptoms 
reported to have an episodic course in the three groups using 3x2 χ2 tests. We used the 
Bonferroni method to correct for multiple comparisons.  
4.4.2 Study II - Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric 
Syndrome (PANS) - Sensitivity and specificity of the Cunningham 
Panel 
The aim of this study was to evaluate the clinical utility of the Cunningham Panel for 
diagnosing PANS and PANDAS. The study design is a diagnostic accuracy study. Two 
methods of diagnosis were applied to the same sample of participants, and the probability that 
the conclusions of the two methods matched was then calculated. The reference standard 
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method of diagnosis was the lengthy diagnostic interview and application of the diagnostic 
criteria for PANS and PANDAS. This diagnosis was compared with the Cunningham Panel 
test diagnosis. Results are presented as sensitivity and specificity of the diagnosis suggested 
by Cunningham Panel results, and as area under the curve of a receiver operating curve. 
Furthermore, test-retest reliability was examined for 10 samples and we also assessed the risk 
of false positive values by testing 21 healthy controls with the Cunningham Panel. See figure 
4 for details.  
 
Figure 4. Procedure of the data collection for study II. (This figure has been previously 
presented in a corrigendum to Study II.50) 
4.4.3 Study III - Patient satisfaction and treatments offered to Swedish 
patients with suspected PANS and PANDAS 
In study III, we aimed to describe the treatments given to a cohort of Swedish patients with 
suspected PANS and PANDAS, the patient rated treatment effects, and to establish if any 
specific treatment predicts higher patient satisfaction. In this study, we only included the 
Cunningham Panel sample, divided into the groups “interview confirmed PANS” and 
“suspected PANS” (see figure 1). We asked each participant to report all treatments they had 
been given for their psychiatric symptoms. We also asked the participants to rate the 
treatment effect of each treatment.  
We present the number of participants in each group who had received each specific 
treatment. We compared the two groups in order to establish if any treatment had been more 
commonly described in any group using χ2 tests. We also compared the relative frequency of 
participants who rated their treatment response to be “much improved” compared to “no or 
little effect” or “worse”, using χ2 tests.  
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In order to determine if patient satisfaction was related to specific treatments we made 
regression models to determine if higher CSQ scores were predicted by specific treatments. 
Since patient satisfaction is known to be associated with global improvement, we have 
controlled this analysis for global improvement. 
4.5 STUDY IV – TREATMENT OF PANDAS AND PANS: A SYSTEMATIC 
REVIEW 
Study IV is a systematic review of all available literature describing treatment of PANS, 
PANDAS or CANS. The aim was to systematically review all published studies in which 
patients with PANS, PANDAS, or the related disorders CANS or PITAND were given 
treatment in order to determine if there is sufficient evidence to recommend specific therapies 
for these patients. This study was carried out according to PRISMA guidelines.51 The 
databases PubMed, Cochrane Library, and Scopus were searched independently for the terms 
(1) “pediatric autoimmune neuropsychiatric disorders associated with strep*.” (2)“pediatric 
acute-onset neuropsychiatric syndrome.” (3) “childhood acute neuropsychiatric symptoms.” 
and (4) “pediatric infection-triggered autoimmune neuropsychiatric disorders.” In Scopus, the 
document type was set to “article.” No filters were applied in searches of Cochrane Library or 
PubMed. Inclusion criteria were articles that (1) applied diagnostic criteria for PANDAS, 
PANS, CANS, or PITAND; (2) presented treatment and outcome data; and (3) were written 
in English. Articles then were categorized as a study or a case report. A study was defined as 
an analytic article of defined treatments with prospectively defined outcome measures. A case 
report was defined as a retrospective presentation of treatment outcomes presented in a 
descriptive article. Case report articles could contain data from single or multiple cases. 
All articles identified as studies were assessed for quality and bias using standardized forms 
prepared by the Swedish Agency for Health Technology Assessment and Assessment of 
Social Services.52, 53 The full texts of all included studies and case reports were read, and data 
comprising study design, number of participants, patients’ symptoms, treatments given and 
reported treatment results were extracted and analysed. The studies and case reports were 
analysed separately and a synthesis of all available data including study results, study 
methods and biases, and case reports, are presented for each treatment reported in the 
literature.  
4.6 ETHICAL CONSIDERATIONS 
Studies I, II and III were approved by the Regional Ethics Review Board of Stockholm at 
Karolinska Institutet (2014/551-31/2; 2014/1711-32; 2015/964-31 and 2016/2121-32). All 
study participants and/or legal guardians granted informed consent. The data collection was 
also registered at clinicaltrials.org prior to enrolment (NCT02190292).  
These studies were conducted in a non-clinical setting. This means that all healthcare 
interventions described in the studies were offered by the patients’ local physician, and not by 
the study. As we did not clinically assess or treat the participants, the risks associated with 
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participation in this study were minimal and mostly related to the integrity of the patients, and 
to discomfort related to blood samples.  
4.6.1 Personal integrity of the participants  
In studies I, II and III we collected data regarding the participants’ health. All data were 
handled confidentially. The information we collected contains identifying information, as 
well as information on participants’ health, and as such it constitutes sensitive personal data. 
Therefore, all data collected within the study must be protected. In order to protect the 
participants’ personal integrity, all personal information is kept securely in coded form. Thus 
each participant was given an anonymous code (a four-digit random number) and this code is 
used as the identifying information in the study. A key connecting each participant to his or 
her anonymous code is kept securely and separate from the clinical data. All data is kept 
securely, locked in a cabinet or on a secure server, in order to minimize the risk of any 
personal data being spread outside the research group.  
4.6.2 Informed consent 
All participants and/or their legal guardians provided informed consent to participate in the 
study. Adult participants with a sufficient level of functioning provided informed consent 
themselves. We did not allow participation consented by parents of adults, if the participant 
him or herself did not consent. However, some of the participants were young, and some had 
little or no spoken language and/or intellectual disability. In these cases, the legal guardian of 
the participant provided informed consent to take part in the study. In order to protect the 
integrity of the participants, no part of the assessment was mandatory for participation, and 
each participant could withdraw from participation in any of the assessments at any time.  
4.6.3 Recruitment method of the Cunningham Panel sample 
As described above, the Cunningham Panel sample was recruited by inviting all patients who 
had taken the panel through Wieslab, which was Moleculera’s partner laboratory in Europe at 
the start of the study. A letter with an initiation to participate to the study was sent out by 
Wieslab. No reminders were sent out to those who did not respond. In order to protect the 
integrity of the patients, the identity of the patients receiving invitation was unknown to the 
research team. The families who wished to participate contacted the research team and were 
enrolled in the study. This recruitment method was approved by the local ethical review 
board.  
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5 RESULTS 
 
SUMMARY OF THE STUDY RESULTS 
 
Study Research Question Method Results Conclusion 
I Do patients with PANS 
differ from other 
psychiatric patients with 
regard to symptoms, 
disorder course or 
symptom load at onset? 
Case control study 
comparing Confirmed 
PANS (n=28), to 
Suspected PANS (n=29) 
and Never PANS (n=32) 
Confirmed PANS (defined as 
acute onset) was associated to an 
episodic course and high 
symptom load at onset. 
Course, acute onset and 
high symptom load at 
onset are better specifiers 
of PANS than presence of 
specific symptoms. 
II Is the Cunningham Panel a 
valid and reliable 
diagnostic measure for 
PANS? 
Diagnostic accuracy 
study comparing 
Cunningham Panel 
results of Confirmed 
PANS (n=24), to 
Suspected PANS (n=29) 
and to a healthy 
comparison sample 
(n=21) 
The Cunningham Panel could 
not differentiate between 
Confirmed and Suspected 
PANS. Healthy controls had 
elevated panel results.  
The Cunningham Panel is 
not clinically useful as a 
diagnostic measure for 
PANS. 
III What treatments are 
offered to Swedish patients 
with PANS, and what are 
their effects? Does 
treatment effect or 
treatment type affect 
patient satisfaction? 
Cross-sectional study of 
patients with Confirmed 
PANS (n=28) and 
Suspected PANS (n=29). 
Patients with PANS are possibly 
under-treated with standard 
psychiatric treatments. However, 
antibiotics and intravenous 
immunoglobulins were 
perceived as helpful. Treatment 
outcome was associated with 
patient satisfaction. 
When treating patients 
with PANS it is important 
to have knowledge of 
both psychiatric and 
immunomodulatory 
treatments. The lack of 
evidence based or 
effective treatments may 
lead to low patient 
satisfaction. 
IV Are there any evidence 
based treatments for 
PANS? 
Systematic review of 
studies (n=12) and case 
reports (n=65) of 
treatment for PANS and 
PANDAS 
Antibiotics, immunomodulatory 
medications and standard 
psychiatric treatment have been 
tried for PANS and PANDAS. 
The evidence for all studied 
treatments is inconclusive. 
The field of PANS and 
PANDAS is in need of 
more and better research 
on the outcome of 
treatments. Key 
methodological issues 
include diagnostic 
challenges and lack of 
relevant outcome 
measures. 
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5.1 STUDY I - CLINICAL FEATURES OF PEDIATRIC ACUTE-ONSET 
NEUROPSYCHIATRIC SYNDROME: FINDINGS FROM A CASE–CONTROL 
STUDY 
53 participants who had previously taken the Cunningham Panel and 36 participants recruited 
in Örebro were included in the study. A total of 28 participants met the criteria for PANS and 
comprise the interview confirmed PANS group in this study. Their current and past 
symptoms, symptoms at onset, and frequency of episodic course was compared to 29 
participants with suspected, but not confirmed PANS, and to 32 participants with current 
psychiatric disorders, but with no suspicion of PANS. Participants with confirmed PANS 
reported a high symptom load at disorder onset and reported more symptoms to have an 
episodic course than the other two groups. In contrast, lifetime frequency of PANS-related 
symptoms as measured with the PANS-Scale R was similar in the confirmed PANS and the 
suspected PANS group. 
Our results indicate that acute-onset PANS is often accompanied by a high symptom load at 
onset, sometimes including severe symptoms like suicidal ideation, and an episodic course. 
These features were more indicative of PANS than the individual psychiatric symptoms and 
therefore we conclude that when assessing and diagnosing PANS, focus should be on the 
onset and course of the disorder, rather than on individual symptoms. 
5.2 STUDY II - BIOMARKERS FOR DIAGNOSIS OF PEDIATRIC ACUTE 
NEUROPSYCHIATRIC SYNDROME (PANS) - SENSITIVITY AND 
SPECIFICITY OF THE CUNNINGHAM PANEL 
In this study, we included the 53 participants who had previously taken the Cunningham 
Panel. We then compared the clinical assessment diagnoses to the diagnoses suggested by the 
Cunningham Panel by calculating sensitivity and specificity. In addition to this, we tested 
test-rest reliability in 10 samples, whether clinical improvement was associated with lower 
Cunningham Panel results in 43 participants, and tested 21 healthy individuals with the panel. 
Our results indicate that the diagnostic accuracy of the panel was low, that test-retest 
reliability of the panel may be unsatisfactory, that 86% of healthy participants had at least one 
positive value of the panel and that clinical improvement was moderately associated with 
clinical improvement for participants meting criteria for PANS or PANDAS, but not for the 
non-PANS or PANDAS group. To conclude, there was no indication that use of the 
Cunningham Panel was beneficial for making a PANS or PANDAS diagnosis in our sample.  
5.3 STUDY III - PATIENT SATISFACTION AND TREATMENTS OFFERED TO 
SWEDISH PATIENTS WITH SUSPECTED PANS AND PANDAS 
In this study, we asked the 53 participants in the Cunningham Panel sample (24 with 
confirmed PANS and 29 with suspected PANS) to report which treatments they had been 
given and to rate the treatment effect. We also tested if patient satisfaction was related to 
specific treatments or to treatment outcome. There were no major differences between 
confirmed and suspected cases regarding what treatments they had been given. The most 
common treatments were antibiotics (88%), NSAIDs (67%), CBT (53%) and SSRIs (42%). 
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Immunological treatments were also common, with 32% having tried IVIG and 19% having 
tried oral corticosteroids for their psychiatric symptoms. The treatments with the best patient 
rated effects were IVIG and antibiotics. Patient satisfaction was higher among participants 
who had received antibiotics and IVIG, but this effect was probably due to global 
improvement.  
To conclude, the participants had been given many different treatments over the years, both 
related directly to their psychiatric symptoms (i.e. psychotropic medications and CBT) and to 
the proposed aetiology of PANS or PANDAS (i.e. antibiotics and IVIG). Patients with 
suspected PANS or PANDAS may be at risk of under-treatment with evidence-based 
treatments such as CBT or SSRIs. However, our results also indicate a risk of non-
satisfactory effects of these treatments.  
5.4 STUDY IV - TREATMENT OF PANDAS AND PANS: A SYSTEMATIC 
REVIEW 
This study is a systematic review of all research studies and case reports in which patients 
with PANS, PANDAS, PITAND or CANS had received treatment. We screened 973 articles 
and assessed 162 full texts to identify a total of 12 studies and 65 case reports describing 
treatment for PANS, PANDAS or PITAND. We could not identify any paper that used the 
diagnostic term CANS to describe a case in this material. The treatments that had been 
systematically studied were; antibiotics (both as prophylaxis and treatment), therapeutic 
plasma exchange, IVIG, tonsillectomy, CBT, NSAIDs, and corticosteroids. In addition, we 
also identified other treatments that have been reported, including SSRIs and other 
psychotropic medications, complementary and alternative medicines and treatments, 
monoclonal anti-CD20 antibodies, sinus surgery, and dietary and other nutrient based 
interventions.  
Based on study findings and risk of bias in the included studies, our results indicate that there 
is no strong evidence to recommend any of the studied treatments. This result is, however, 
not an effect of studies indicating that these treatments are unhelpful, but rather a product of 
the studies being too few, of too low quality, too small, and the lack of appropriate outcome 
measures. There is clearly a need for more high quality treatment studies within the field of 
PANS and PANDAS.  
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6 DISCUSSION 
6.1 AIM 1: TO DESCRIBE A SWEDISH COHORT OF PATIENTS WITH PANS 
AND PANDAS 
We have described a cohort of 53 Swedish patients, all assessed with the Cunningham Panel 
and thus with a suspicion of PANS. In Study I, we describe the symptoms, onset and course 
of their disorders in detail. We have also contrasted patients with suspected PANS to 
psychiatric patients with no suspicion of PANS. In Study II, we describe the Cunningham 
Panel results in our cohort, and in Study III, we describe the treatments they had received 
and the participants’ satisfaction with the healthcare services received.  
In general, all the participants who had previously taken the Cunningham Panel were or had 
been very ill. The participants who did not meet full criteria for PANS presented more severe 
symptoms at the time of our assessment. Many participants who did not meet full PANS 
criteria (i.e. without acute onset) presented with many symptoms that are associated with 
PANS. All participants had received treatments for their conditions, regardless if they met the 
PANS criteria or not. Some treatments were based on the proposed pathophysiology of 
PANS and PANDAS and thus included antibiotics and NSAIDs. Our findings are similar to 
those of previously published data from clinical studies10, 26, 40 and a large survey study on 
PANS and PANDAS.54, 55 
6.1.1 Methodological issues  
6.1.1.1 What is a diagnosis of PANS or PANDAS? 
This thesis is built on the premises that a) PANS and PANDAS are clinical entities that are 
identifiable through clinical examination and b) the clinical examination performed during 
the data collection was of such quality that the classifications we made are valid. None of 
these premises are however necessarily true.23 The PANDAS and PANS criteria used today 
are still the research criteria proposed in 19981 and 2012.2 However, PANDAS has been 
proven hard to distinguish from non-PANDAS OCD regarding exacerbations following 
streptococcal infections,21, 56 and PANS has also been difficult to distinguish from non-PANS 
regarding the symptoms experienced in clinical samples26 including ours, as presented in 
Study I.  
Nevertheless, the criteria from 1998 and 2012 are the only ones available, and therefore used 
in our study. We consider the assessment of the patients and the classification of PANS and 
PANDAS that we made to be a gold standard psychiatric assessment, and it has some key 
characteristics that imply high quality: it was carried out by an expert in psychiatry, 
specifically neuropsychiatry, OCD and psychiatric diagnosis, it comprised medical and 
psychiatric history and status, and included a motor assessment (that was filmed) as well as a 
cognitive assessment, it used a structured interview for PANS-relevant symptoms and gold 
standard instruments of psychiatric symptoms such as the CY-BOCS and the MINI-KID. 
However, it did not include an exclusion of all possible other causes of neuropsychiatric 
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symptoms, neuroimaging or extensive biochemical testing, which are recommended by a 
consortium of PANS researchers.11 
Despite these weaknesses, we were able to identify that participants who fulfilled PANS 
criteria, rated more of their symptoms to have an episodic course than other psychiatric 
patients. We were also able to show that participants fulfilling full PANS criteria report more 
psychiatric symptoms, including severe symptoms like suicidal ideations, at disorder onset 
than other psychiatric patients. However, we have not tested whether or not this particular 
clinical picture, with acute onset, severe symptoms already at onset and an episodic course, is 
in fact related to an immunological pathogenesis.  
6.2 AIM 2: TO EVALUATE THE UTILITY OF THE CURRENT DIAGNOSTIC 
CRITERIA FOR PANS AND PANDAS 
Participants who had previously taken the Cunningham Panel had similar symptom histories, 
regardless if they met full criteria for PANS or not. This parallels the results from a PANS 
clinic at Stanford university.26 At the Stanford clinic, they assessed and treated 47 patients 
who met symptom criteria for PANS, although only 19 of the patients presented with an acute 
onset, thus meeting full PANS criteria. Furthermore, the PANS and non-PANS patients of the 
Stanford clinic were similar regarding laboratory test results and symptom history.26 In Study 
I, the main differences identified between the three groups were that the participants who 
fulfilled full criteria for PANS reported multiple and severe symptoms at disorder onset and 
that more of their symptoms had lead an episodic course. Likewise, it was unusual for 
psychiatric patients without prior suspicion of PANS to report an acute onset of symptoms. 
Only 5 of the 36 participants recruited through the Örebro sample reported having had an 
acute onset, and 4 of these met full PANS criteria.  
A diagnostic category can be used for several reasons, and the clinically most important 
purpose is to guide the choice of treatment. Many of the participants in Study III, both 
fulfilling and not fulfilling full PANS criteria, had received treatments based on the 
assumption that their symptoms had an immunological pathogenesis. Indeed, many of the 
participants found these treatments helpful, whether they fulfilled the complete PANS criteria 
or not.  
This thesis provides no definite answer to the question of the clinical utility of today’s 
diagnostic criteria for PANS and PANDAS. However, these patients exist, and they have 
multiple and severe symptoms regardless how we classify them. Patients with suspected 
PANS or PANDAS need medical expertise, somatic and psychiatric assessment and helpful 
treatments. Importantly, they need to be met with respect and compassion, as pointed out by 
the European advocacy organisations.57 
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6.3 AIM 3: TO EVALUATE THE DIAGNOSTIC ACCURACY OF THE 
CUNNINGHAM PANEL, A SET OF BIOMARKERS AIMING TO DIAGNOSE 
PANS AND PANDAS 
In Study II, we demonstrate that in our sample of Swedish patients with suspected or 
confirmed PANS, the Cunningham Panel did not contribute to an accurate diagnosis. This 
interpretation is supported by low specificity and low diagnostic accuracy, a high proportion 
of healthy participants having a positive result on at least one analyte of the panel, and by low 
test-retest reliability. However, decreased Cunningham Panel results was moderately 
associated with improvement of global function among participants with confirmed PANS or 
PANDAS. Yet, our main conclusion is that the Cunningham Panel may have been introduced 
prematurely as a diagnostic marker for PANS and PANDAS. As a consequence of our 
findings, Wieslab no longer markets the Cunningham Panel in Europe.  
6.3.1 Methodological issues of Study II 
6.3.1.1 Did we use the wrong tubes?  
When Study II had been published, we received a message from Moleculera labs stating that 
the blood collection tubes used in our study was not the kind recommended by Moleculera 
Labs. Therefore, we have published a corrigendum to this paper, with details of the tubes that 
were used.50 Moleculera recommend use of a glass tube with no additives for serum 
collection. At the time of the study, Wieslab wrote in their instructions that serum separating 
tubes with or without gel could be used. Furthermore, the use of glass tubes is rare in 
Sweden, instead they have been replaced with plastic tubes. In order to mimic the coagulant 
effect of glass, silica is added to plastic serum collection tubes, which means that plastic 
serum collection tubes are not “additive free”. 
In the main analysis of Study II we used the test results available through the records kept by 
Wieslab. Wieslab does not keep a record of which tubes were used for sample collection and 
therefore the information on which tubes were used at time point 1 is unavailable. Assuming 
that the blood samples were made according to the instructions given by Wieslab, samples 
were taken in serum tubes, with or without a separator gel. These instructions were both 
printed on the form that is used to order the test, and presented on Wieslab’s home page, 
along with pictures of the approved red-top and gold-top tubes. Since the use of glass tubes is 
uncommon in Sweden, most samples were probably taken in plastic tubes. 
In the corrigendum that we published50 we make the arguments that since use of plastic 
serum collection tubes with a separator gel are standard tubes for collecting serum for 
analysing antibodies in Sweden, it is unlikely that the antibodies measured in the 
Cunningham panel would be affected by the use of these tubes.  
The same is however not true for the CaMKII activation analysis, which is a cell based assay 
only performed at Moleculera Labs. Here we instead argue that the most probable effect a 
serum separator gel has on a sample is that some compounds with a molecular weight similar 
to that of the gel may get caught in the gel, which would reduce the amount of the compound 
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in serum, thereby most probably leading to false low test results. Since 46% of our healthy 
sample had elevated levels of CaMKII (which suggests illness), the weak diagnostic 
properties of the panel in our sample do not stem from false low levels.  
Furthermore, we tested the clinical utility of the panel as it was managed in Europe at the 
time of our study, which included use of plastic tubes and tubes with a separator gel.  
6.3.1.2 Why compare confirmed PANS to suspected PANS? 
Our main argument regarding the low clinical validity of the panel as a diagnostic tool for 
PANS or PANDAS is however that we tested the clinical utility of the panel. We designed 
the study to follow STARD guidelines,39 which is a set of guidelines for the study and 
reporting of diagnostic instruments or tests. The STARD guidelines point out that a test can 
be used for several reasons and that the study design must mirror the intended clinical use of 
the test. A diagnostic test should have a high positive predictive value when used in a 
population where it is likely to be clinically used. STARD guidelines propose that diagnostic 
tests should be evaluated in a sample that is as close to the clinical sample where the test is 
likely to be used, i.e. to test the diagnostic properties between true cases and suspected cases 
of the disorder, rather than between true cases and healthy controls. We argue that the sample 
we have recruited are highly likely to be similar to the population likely to be tested clinically 
with the Cunningham Panel. They were all very ill and they had been clinically tested with 
the panel for some reason.  
To conclude, the 53 participants in our study are highly representative for patients likely to be 
tested with the Cunningham Panel. We were blinded to Cunningham Panel results when we 
made the clinical classification of PANS or PANDAS. Thus, we used the gold standard for 
reporting the diagnostic accuracy of a test.  
6.3.1.3 What do we mean by suspected PANS? 
Although we assume that it was because of suspicion of PANS or PANDAS, we do not know 
the reason why our participants took the Cunningham Panel. The only indication for taking 
the panel is diagnoses of PANS and PANDAS. However, in 4 cases, we do know the reason 
for referral and it was due to inclusion in another research study, and not because of suspicion 
of PANS. These patients were severely ill patients with psychosis and their test was ordered 
as a part of the study Stockholm Child and Adolescent Psychosis Study (SCAPS), run by Dr. 
Mathias Lundberg at Karolinska Institutet. We were not aware of this study at the time of 
inclusion (even though it took place at the same university as our project). However, we do 
not think that this is a major limitation to our study, since children and adolescents with 
psychosis and severe symptoms may be a suitable control population for a diagnostic test for 
PANS and PANDAS. These participants were assessed for PANS and PANDAS in 
accordance with our study protocol and in the same manner as all other participants. 
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6.3.2 Can the Cunningham Panel still be useful? 
Even though the Cunningham Panel’s ability to separate PANS from non-PANS cases was 
limited in our study, the panel has been suggested to be of use as a predictor of treatment 
response to IVIG. A recent study where children with autism and autoimmune 
encephalopathy were treated with IVIG used the Cunningham Panel as a diagnostic marker 
for autoimmune encephalopathy.58 This is however the first published use of the Cunningham 
Panel as a marker for autoimmune encephalopathy, and the panel’s validity for such use is 
unclear. Moreover, the study suggests that the Cunningham Panel could be used to predict 
treatment outcome.58 However, since one of the inclusion criteria for receiving IVIG was to 
have a positive panel, the true value of the Cunningham Panel as a predictor of outcome is 
still untested. Dr. Bejerot and myself have written a letter raising concerns about using the 
Cunningham Panel for diagnostic purposes.59 We have received a response from Moleculera 
and the authors of Connery et al. stating that our criticism of the panel is based on a faulty 
recruitment of healthy controls, and the use of non-recommended sampling tubes.60 
In the largest study hitherto of IVIG as a treatment for PANDAS, elevated CaMKII and 
antinuclear antibodies (ANA) was associated with a greater treatment response to IVIG.34 
This was however a post hoc finding, and only 7 participants in the IVIG group and 4 
participants in the placebo group were positive for CaMKII and ANA. Consequently, the 
analysis of the study is too underpowered to be definite. The utility of the Cunningham Panel 
as a marker for future treatment response to IVIG is thus still untested.  
6.4 AIM 4: TO ESTABLISH IF THERE ARE CURRENTLY ANY EVIDENCE 
BASED TREATMENTS FOR PANS OR PANDAS 
In Study IV we reviewed the current literature of treatment of PANS, PANDAS, CANS and 
PITAND, including published case series and case reports. We could find no strong evidence 
for any of the treatments that have been studied in PANS or PANDAS. This is however likely 
a result of the research methods used (small numbers, unclear diagnostic criteria used, 
multiple and sometimes unsuitable outcome measures used) and not a fair assessment of the 
actual efficacy of treatments for PANS and PANDAS. The many case reports and the 
experience from the clinics dedicated to PANS and PANDAS sing a different tune than the 
studies published. The many case reports, case series and the consensus papers on 
treatment61-63 that have been published in combination with the specialist centres being 
established across the world suggest that patients are being treated for PANS and PANDAS 
today, even though the evidence is weak. Thus, there is evidently a need for more well-made 
treatment studies of PANS and PANDAS, or otherwise testing immunological treatments in 
psychiatric conditions with a suspected immunological pathogenesis. 
6.5 AIM 5: TO DESCRIBE THE TREATMENTS GIVEN TO A SWEDISH SAMPLE 
OF PATIENTS WITH PANS AND PANDAS, AND THE TREATMENT 
EFFECTS 
In Study III we present data on the 53 participants with suspected and interview confirmed 
PANS and PANDAS and what treatments they had been given. Our results are similar to a 
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large survey study of 698 patients with PANS54 which also indicated that treatment with 
antibiotics was very common, as were other immunological treatments. Furthermore, we also 
found similar results as another Swedish cohort of PANS, which also indicated that 
antibiotics was commonly received and reported to be helpful in a majority of cases.40 
However, our results are retrospectively rated by patients, and therefore possibly influenced 
by both recall bias and by expectation phenomena, thus they must be interpreted with caution. 
In favour of the PANS or PANDAS idea is however the fact that many cohorts seem to have 
similar findings: treatments based on the idea of an immunological pathogenesis are 
requested by the patients, and they often rate them as beneficial. However, when PANS and 
PANDAS are systematically tested it has been proven hard to find evidence for 
autoimmunity, biomarkers and treatment effect.23 
6.6 FUTURE DIRECTIONS 
Since the beginning of our study, two specialist centres for children and adolescents with 
PANS and PANDAS have been established in Sweden. A patient organisation (Sane - 
Förbundet autoimmuna encefaliter med psykiatrisk presentation) has started and organises 
activities such as telephone support for families and social activities in addition to arranging a 
large international research conference to be held in the autumn of 2019. Knowledge of 
PANS and PANDAS is increasing, as is the demand from patients to receive a diagnosis and 
treatment. Nevertheless, the evidence for diagnosis and treatment of PANS and PANDAS is 
still weak, and more research is urgently needed.  
Epidemiology may help to disentangle the relationship between psychiatry, specifically OCD, 
eating disorder and tics, inflammation and infections. Recent advances in this field include an 
association between low levels of serum immunoglobulin A and childhood onset OCD,64 and 
an elevated risk of eating disorders after exposure to infections.65 However, these studies are 
association studies based on insurance claim data, or on national registers, and to fully 
disentangle these associations, study designs using more detailed clinical data may be 
advised.  
The field of PANS and PANDAS lacks psychometrically sound tools for both diagnosis and 
for evaluating change over time or treatment effects. Future research should include a 
systematic evaluation of the diagnostic protocols that have been proposed.11, 66 The treatment 
studies we have reviewed have all used slightly different inclusion criteria, and this of course 
complicates interpretation of the results. Moreover, most treatment studies have used single 
dimension outcome measures (most commonly CY-BOCS), even though PANS and 
PANDAS are defined as multi-dimensional disorders. Two studies used “duration of flare” as 
outcome measure, instead of disorder severity at a specific timepoint.37, 38 This approach is 
more in line with the clinical features of PANS and PANDAS, but there is currently no 
validated measure of what constitutes a PANS-flare, or how to measure flare duration. 
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6.7 CONCLUSIONS 
We have described a Swedish sample of patients with suspected and confirmed PANS or 
PANDAS. Our findings confirm previous research, that patients with PANS and PANDAS 
have severe and mixed symptoms. We also found that the symptoms of patients with PANS 
and PANDAS often are shared with psychiatric patients with no suspicion of PANS, but that 
acute onset is associated with multiple and severe symptoms at onset, and with an episodic 
course. We therefore suggest that these characteristics are of importance when diagnosing 
PANS and PANDAS. The Cunningham Panel is not a reliable diagnostic measure for PANS 
or PANDAS, and although biomarkers may serve a purpose as pathophysiological clues, it is 
important to fully test the clinical validity before proposing that elevated levels of a marker 
suggest a specific diagnosis. When treating patients with PANS it is important to have 
knowledge of both psychiatric and immunomodulatory treatments. It is also important to note 
that the lack of evidence based or effective treatments may lead to a low patient satisfaction. 
The field of PANS and PANDAS is in need of more and better research on the outcome of 
treatments given, both within a psychiatric and immunological treatment paradigm. Another 
urgent task for PANS and PANDAS research is to develop better diagnostic tools that can 
identify patients likely to be helped with immunomodulatory treatments, and to develop 
outcome measures that consider general function and disorder course, rather than individual 
psychiatric symptoms.  
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